









Markets
/
Stocks
/
nasdaq-ocul
/

Ocular Therapeutix Inc

OCUL

11.220USD

+0.390+3.60%

Close 11/11, 16:00（ET）Quotes delayed by 15 min

1.96BMarket Cap

LossP/E TTM



Ocular Therapeutix Inc

11.220

+0.390+3.60%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Company

Financials

Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Ocular Therapeutix Inc

Currency: USD Updated: 2025-11-10

Key Insights

The company's fundamentals are relatively very healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. Despite an average stock market performance, the company shows strong fundamentals and technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Ocular Therapeutix Inc's Score

Industry at a Glance

Industry Ranking

68 / 159

Overall Ranking

181 / 4611

Industry

Pharmaceuticals

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 13 analysts

Buy

Current Rating

22.333

Target Price

+105.84%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Ocular Therapeutix Inc Highlights

StrengthsRisks

Ocular Therapeutix, Inc. is a biopharmaceutical company. The Company is engaged in the development and commercialization of therapies for wet age-related macular degeneration (wet AMD), diabetic retinopathy, and other diseases and conditions of the eye. Its first commercial drug product, DEXTENZA, is for the treatment of ocular inflammation and pain following ophthalmic surgery and ocular itching associated with allergic conjunctivitis. It is also developing two other clinical-stage assets, OTX-DED (dexamethasone intracanalicular insert) for the short-term treatment of the signs and symptoms of dry eye disease, and OTX-CSI (cyclosporine intracanalicular insert) for the chronic treatment of dry eye disease. It is conducting a pivotal Phase III clinical trial to evaluate AXPAXLI for the treatment of wet AMD. Its clinical portfolio also includes PAXTRAVA, which is in Phase III clinical development for the treatment of primary open-angle glaucoma (OAG) or ocular hypertension (OHT).

High Growth

The company's revenue has grown steadily over the past 3 years, averaging 23.75% year-on-year.

Growing

The company is in a growing phase, with the latest annual income totaling USD 63.72M.

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 63.72M.

Undervalued

The company’s latest PE is -7.55, at a low 3-year percentile range.

Institutional Buying

The latest institutional holdings are 156.52M shares, increasing 4.57% quarter-over-quarter.

Held by Invesco

Star Investor Invesco holds 1.46M shares of this stock.

Financial Health

Currency: USD Updated: 2025-11-10

The company's current financial score is 6.38, which is lower than the Pharmaceuticals industry's average of 7.76. Its financial status is robust, and its operating efficiency is low. Its latest quarterly revenue reached 14.54M, representing a year-over-year decrease of 5.71%, while its net profit experienced a year-over-year decrease of 90.22%.

Score

Industry at a Glance

Previous score

6.38

Change



Financials

9.12

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

7.24

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

2.57

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

5.86

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

7.11

Key Metrics

Free cash flow

No Data

Ocular Therapeutix Inc's Company Valuation

Currency: USD Updated: 2025-11-10

The company’s current valuation score is 6.61, which is lower than the Pharmaceuticals industry's average of 7.21. Its current P/E ratio is -7.55, which is -68.37% below the recent high of -2.39 and -43.12% above the recent low of -10.81.

Score

Industry at a Glance

Previous score

6.61

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 68/159

No Data

Earnings Forecast

Currency: USD Updated: 2025-11-10

The company’s current earnings forecast score is 8.77, which is higher than the Pharmaceuticals industry's average of 7.77. The average price target for Ocular Therapeutix Inc is 21.00, with a high of 31.00 and a low of 18.00.

Score

Industry at a Glance

Previous score

8.77

Change

Support & Resistance

No Data

Analyst Rating

Based on 13 analysts

Buy

Current Rating

22.333

Target Price

+106.22%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

169

Total

Median

Average

Company name

Ratings

Analysts

Ocular Therapeutix Inc

OCUL

Biogen Inc

BIIB

Amgen Inc

AMGN

Vertex Pharmaceuticals Inc

VRTX

Eli Lilly and Co

LLY

AbbVie Inc

ABBV

...

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-11-10

The company’s current price momentum score is 6.93, which is lower than the Pharmaceuticals industry's average of 7.09. Sideways: Currently, the stock price is trading between the resistance level at 12.01 and the support level at 9.98, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

6.95

Change

-0.02

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(2)

Neutral(3)

Buy(2)

Indicators

Value

Direction

MACD(12,26,9)

-0.075

Sell

RSI(14)

46.677

Neutral

STOCH(KDJ)(9,3,3)

39.278

Buy

ATR(14)

0.456

High Vlolatility

CCI(14)

-33.757

Neutral

Williams %R

48.889

Neutral

TRIX(12,20)

-0.322

Sell

StochRSI(14)

100.000

Buy

Moving Average

Sell(3)

Neutral(0)

Buy(3)

Indicators

Value

Direction

MA5

10.868

Buy

MA10

11.161

Buy

MA20

11.444

Sell

MA50

11.898

Sell

MA100

11.635

Sell

MA200

9.613

Buy

Institutional Confidence

Currency: USD Updated: 2025-11-10

The company’s current institutional recognition score is 7.00, which is higher than the Pharmaceuticals industry's average of 5.76. The latest institutional shareholding proportion is 73.70%, representing a quarter-over-quarter decrease of 11.62%. The largest institutional shareholder is The Vanguard, holding a total of 9.14M shares, representing 4.29% of shares outstanding, with 20.06% decrease in holdings.

Score

Industry at a Glance

Previous score

7.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

Fidelity Management & Research Company LLC

18.57M

+1941.54%

Deep Track Capital LP

14.29M

VR Adviser, LLC

12.76M

Summer Road, LLC

13.89M

+0.07%

BlackRock Institutional Trust Company, N.A.

9.34M

-13.64%

The Vanguard Group, Inc.

Star Investors

8.37M

+0.33%

Avoro Capital Advisors LLC

7.40M

-8.19%

TCG Crossover Management, LLC

5.32M

Citadel Advisors LLC

4.89M

+1.56%

Adage Capital Management, L.P.

3.89M

-25.19%

Risk Assessment

Currency: USD Updated: 2025-11-10

The company’s current risk assessment score is 6.00, which is higher than the Pharmaceuticals industry's average of 5.15. The company's beta value is 0.98. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.